Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
A Randomized, Double-Blind, Phase 2 Trial of Once-Weekly Petrelintide Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes
Sponsor: Parexel
A PHASE2 clinical study on Obesity and Overweight, this trial is ongoing. The trial is conducted by Parexel and has accumulated 6 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2025 — Jan 2026 [monthly]
Recruiting PHASE2
-
Aug 2025 — Nov 2025 [monthly]
Recruiting PHASE2
-
Jun 2025 — Aug 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
May 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Apr 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Parexel
- Zealand Pharma
For direct contact, visit the study record on ClinicalTrials.gov .